ICCC FY 2023 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M-5.9% YoY

Gross Profit

$4M25.2% margin

Operating Income

-$6M-32.9% margin

Net Income

-$6M-33.1% margin

EPS (Diluted)

$-0.75

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$7M

Stock-Based Comp.

$368,866

Balance Sheet

Total Assets

$44M

Total Liabilities

$19M

Stockholders' Equity

$25M

Cash & Equivalents

$978,741

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$19M	-5.9%
Gross Profit	$4M	$8M	-42.5%
Operating Income	-$6M	-$2M	-150.0%
Net Income	-$6M	-$2M	-131.5%